Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSavills Regulatory News (SVS)

Share Price Information for Savills (SVS)

Share Price is delayed by 15 minutes
Get Live Data
808.00    -10.00 (-1.22%)
Bid:
811.00
Ask:
813.00
Spread: 2.00 (0.247%)
Market Cap: £1.12b
SVS Live PriceLast checked at - London Stock Exchange

Intraday Savills Share Chart

Director/PDMR Shareholding

26 Apr 2024 14:13

RNS Number : 2632M
Savills PLC
26 April 2024
 

SAVILLS PLC (THE "COMPANY")

TRANSACTION IN SHARES BY DIRECTORS AND PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMRS)

 

Vesting of Share Awards

 

Awards over ordinary shares of the Company under the Deferred Share Plan have become unconditional in all respects following the end of their Deferred Period. In satisfaction of the Awards, the Trustee of the Savills US Employee Benefit Trust effected the transfer of shares, following the settlement of associated tax liabilities through the sale of shares, to a PDMR of the Company based in North America as follows:-

 

 

PDMR

Number of Shares Transferred

Number of Shares Disposed

Shareholding following this notification

Shareholding as a % of issued share capital

David Lipson

39,058

19,488

103,699

0.07%

 

The share price on disposal of shares was £10.45 per share.

 

 

Grant of Share Awards

 

The Company announces that on 24 April 2024 the grant of the share-based element of 2023 profit share awards has been made under the Savills Deferred Share Bonus Plan to Directors and PDMRs as follows:-

 

Director/ PDMR

Number of shares subject to the Savills Deferred Share Bonus Plan awarded to the Director/ PDMR on 24 April 2024

Mark Ridley (Director)

58,841

Simon Shaw (Director)

45,105

Alex Jeffrey (PDMR)

18,234

Chris Lee (PDMR)

9,596

Raymond Lee (PDMR)

41,266

David Lipson (PDMR)

7,712

Christian Mancini (PDMR)

7,869

James Sparrow (PDMR)

33,589

These awards have a Deferred Period of three years and are subject to rolled-up dividend shares whereby the number of shares awarded will be increased on the vesting date to reflect final and interim dividends declared during the Deferred Period.

 

The Company announces that on 24 April 2024 the grant of an award has been made under The Schedule to The Savills Deferred Share Plan to a PDMR based in the United States of America as follows:-

 

PDMR

Number of shares subject to the Savills Deferred Share Plan awarded to the PDMR on 24 April 2024

David Lipson (PDMR)

38,563

One-third of Mr Lipson's award will vest on each of the three anniversaries subsequent to the date of grant subject to continued employment and performance. The award is subject to rolled-up dividend shares whereby the number of shares awarded will be increased on the vesting dates to reflect final and interim dividends declared during the Deferred Periods.

Resulting beneficial interests under the Savills Deferred Share Bonus Plan and Savills Deferred Share Plan further to the above notifications are as follows:

Director/ PDMR

Resulting beneficial interest under the Savills Deferred Share Bonus Plan and Savills Deferred Share Plan

Mark Ridley (Director)

281,493

Simon Shaw (Director)

214,056

Alex Jeffrey (PDMR)

307,184

Chris Lee (PDMR)

74,917

Raymond Lee (PDMR)

171,840

David Lipson (PDMR)

151,801

Christian Mancini (PDMR)

146,303

James Sparrow (PDMR)

163,057

 

 

The information set out below is provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation No 596/2014.

1.

Details of the Director/ PDMR

 

(a)

Name

1. Mark Ridley

2. Simon Shaw

3. Alex Jeffrey

4. Chris Lee

5. Raymond Lee

6. David Lipson

7. Christian Mancini

8. James Sparrow

 

2.

Reason for the notification

 

(a)

Position/ status

1. Group Chief Executive/ Director

2. Group Chief Financial Officer/ Director

3. Chief Executive Officer - Savills Investment Management/ PDMR

4. Group Legal Director and Company Secretary/ PDMR

5. Chief Executive - Hong Kong, Macau and Greater China/ PDMR

6. Chief Executive Officer - Savills North America/ PDMR

7. Chief Executive Officer - Asia Pacific (ex-Greater China)/ PDMR

8. Chief Executive Officer, UK & CEME/ PDMR

 

(b)

Initial notification/ Amendment

 

Initial notification

3.

Details of the issuer

 

(a)

Name

Savills plc

 

(b)

LEI

213800WXICGMBWHTA933

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

(a)

Description of the Financial Instrument

 

Savills plc Ordinary Shares of 2.5p each

(b)

Identification code of the Financial Instrument

 

GB00B135BJ46

(c)

Nature of the transaction

 

1) Vesting of awards under the Company's Deferred Share Plan and sale of shares to satisfy associated tax liabilities

2) Grant of awards over Ordinary Shares in accordance with the Company's Deferred Share Bonus Plan and Deferred Share Plan

 

(d)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

1)

Acquisition

£nil per share

 

 

 

 

 

 

 

Disposal

£10.45 per share

1. n/a

2. n/a

3. n/a

4. n/a

5. n/a

6. 39,058

7. n/a

8. n/a

9. n/a

 

1. n/a

2. n/a

3. n/a

4. n/a

5. n/a

6. 19,488

7. n/a

8. n/a

9. n/a

 

2)

£nil per share

1. 58,541

2. 45,105

3. 18,234

4. 9,596

5. 41,266

6. 46,275

7. 7,869

8. 33,589

(e)

Aggregated information

 

- Aggregated volume

- Price

 

N/A

 

 

(f)

Date of the transaction

 

24 April 2024

(g)

Place of the transaction

 

Outside a trading venue

 

Name of contact and telephone number for queries:

Chris Lee

Group Legal Director & Company Secretary

020 3107 5444

 

26 April 2024

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHMZGZDFVMGDZM
Date   Source Headline
1st Jun 202611:29 amRNSTotal Voting Rights
22nd May 202610:09 amRNSDirector/PDMR Shareholding
14th May 202612:41 pmRNSResult of AGM
13th May 20264:16 pmRNSResult of AGM
13th May 20267:00 amRNSAGM Statement
12th May 20263:41 pmRNSDirector/PDMR Shareholding
7th May 20263:39 pmRNSDirector Declaration
29th Apr 20263:04 pmRNSReplacement - Director/PDMR Shareholding
29th Apr 20261:23 pmRNSDirector/PDMR Shareholding
28th Apr 20261:58 pmRNSDirector/PDMR Shareholding
13th Apr 20265:24 pmRNSHolding(s) in Company
13th Apr 20262:10 pmRNSDirector/PDMR Shareholding
7th Apr 20264:03 pmRNSAnnual Report and AGM Notice
1st Apr 202610:00 amRNSTotal Voting Rights
31st Mar 202612:55 pmRNSDirector/PDMR Shareholding
26th Mar 20268:57 amRNSDirector/PDMR Shareholding
24th Mar 202611:02 amRNSDirector/PDMR Shareholding
23rd Mar 20269:27 amRNSDirector/PDMR Shareholding
18th Mar 20263:47 pmRNSDirector/PDMR Shareholding
16th Mar 20262:33 pmRNSHolding(s) in Company
16th Mar 20262:33 pmRNSHolding(s) in Company
16th Mar 20262:00 pmRNSHolding(s) in Company
16th Mar 20262:00 pmRNSHolding(s) in Company
16th Mar 202611:51 amRNSDirector/PDMR Shareholding
16th Mar 202611:51 amRNSDirector/PDMR Shareholding
16th Mar 202611:49 amRNSDirector/PDMR Shareholding
16th Mar 202611:49 amRNSDirector/PDMR Shareholding
13th Mar 20261:34 pmRNSDirector/PDMR Shareholding
13th Mar 20261:32 pmRNSDirector/PDMR Shareholding
12th Mar 20267:26 amRNSSignificant Transaction
12th Mar 20267:26 amRNSSignificant Transaction
12th Mar 20267:08 amRNSFinal Results
11th Mar 20264:21 pmRNSDirector/PDMR Shareholding
11th Mar 20264:21 pmRNSDirector/PDMR Shareholding
5th Mar 20265:00 pmRNSHolding(s) in Company
2nd Mar 20269:11 amRNSTotal Voting Rights
25th Feb 202611:14 amRNSHolding(s) in Company
11th Feb 20264:07 pmRNSDirector/PDMR Shareholding
4th Feb 20265:29 pmRNSHolding(s) in Company
2nd Feb 20265:32 pmRNSTotal Voting Rights
19th Jan 20268:30 amRNSDirectorship change
15th Jan 20267:00 amRNSYear End Trading Update
13th Jan 20265:40 pmRNSDirector/PDMR Shareholding
13th Jan 202612:59 pmRNSHolding(s) in Company
2nd Jan 20263:00 pmRNSTotal Voting Rights
11th Dec 20252:00 pmRNSDirector/PDMR Shareholding
1st Dec 20259:49 amRNSTotal Voting Rights
11th Nov 20254:58 pmRNSDirector/PDMR Shareholding
3rd Nov 202512:32 pmRNSTotal Voting Rights
13th Oct 20251:33 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.